AR080216A2 - Composiciones farmaceuticas que contienen una proteina de fusion de vih - Google Patents

Composiciones farmaceuticas que contienen una proteina de fusion de vih

Info

Publication number
AR080216A2
AR080216A2 ARP110100503A ARP110100503A AR080216A2 AR 080216 A2 AR080216 A2 AR 080216A2 AR P110100503 A ARP110100503 A AR P110100503A AR P110100503 A ARP110100503 A AR P110100503A AR 080216 A2 AR080216 A2 AR 080216A2
Authority
AR
Argentina
Prior art keywords
fusion protein
pharmaceutical compositions
compositions containing
hiv fusion
gag
Prior art date
Application number
ARP110100503A
Other languages
English (en)
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of AR080216A2 publication Critical patent/AR080216A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
    • A61K2039/645—Dendrimers; Multiple antigen peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Una composicion farmacéutica que comprende una proteína de fusion de VIH que comprende Nef, RT y p17 Gag y p24 Gag, en la que hay al menos un antigeno de VIH entre p17 Gag y p24Gag o el o los polinucleotidos que la codifican, junto con un vehículo o adyuvante farmacéuticamente aceptable.
ARP110100503A 2004-08-05 2011-02-18 Composiciones farmaceuticas que contienen una proteina de fusion de vih AR080216A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0417494.2A GB0417494D0 (en) 2004-08-05 2004-08-05 Vaccine

Publications (1)

Publication Number Publication Date
AR080216A2 true AR080216A2 (es) 2012-03-21

Family

ID=32982606

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP050103260A AR050102A1 (es) 2004-08-05 2005-08-04 Polipeptidos de fusion de vih para la prevencion y /o tratamiento del sida
ARP110100503A AR080216A2 (es) 2004-08-05 2011-02-18 Composiciones farmaceuticas que contienen una proteina de fusion de vih

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP050103260A AR050102A1 (es) 2004-08-05 2005-08-04 Polipeptidos de fusion de vih para la prevencion y /o tratamiento del sida

Country Status (31)

Country Link
US (2) US7612173B2 (es)
EP (3) EP2130921B1 (es)
JP (3) JP2008507987A (es)
KR (1) KR101501495B1 (es)
CN (2) CN102633866B (es)
AR (2) AR050102A1 (es)
AT (1) ATE443769T1 (es)
AU (1) AU2005268856B2 (es)
BR (1) BRPI0514108A (es)
CA (1) CA2575898C (es)
CY (1) CY1109667T1 (es)
DE (1) DE602005016810D1 (es)
DK (1) DK1773999T3 (es)
ES (3) ES2486669T3 (es)
GB (1) GB0417494D0 (es)
HR (1) HRP20090678T1 (es)
IL (2) IL180947A0 (es)
MA (1) MA28983B1 (es)
MX (1) MX2007001515A (es)
MY (1) MY145614A (es)
NO (1) NO20070988L (es)
NZ (1) NZ552976A (es)
PE (1) PE20060577A1 (es)
PL (1) PL1773999T3 (es)
PT (1) PT1773999E (es)
RU (1) RU2441878C2 (es)
SG (1) SG155206A1 (es)
SI (1) SI1773999T1 (es)
TW (1) TWI365191B (es)
WO (1) WO2006013106A2 (es)
ZA (1) ZA200700771B (es)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020048596A1 (en) * 1994-12-30 2002-04-25 Gregor Cevc Preparation for the transport of an active substance across barriers
EP1039880A1 (en) * 1998-10-23 2000-10-04 Idea Innovative Dermale Applikationen GmbH Method for developing, testing and using associates of macromolecules and complex aggregates for improved payload and controllable de/association rates
DE69901377T2 (de) 1999-01-27 2003-01-02 Idea Ag Nichtinvasive Impfung durch die Haut
ATE216223T1 (de) 1999-01-27 2002-05-15 Idea Ag Transnasaler transport bzw. impfung mit hochadaptierbaren trägern
WO2001001962A1 (en) * 1999-07-05 2001-01-11 Idea Ag. A method for the improvement of transport across adaptable semi-permeable barriers
US7473432B2 (en) * 2002-10-11 2009-01-06 Idea Ag NSAID formulations, based on highly adaptable aggregates, for improved transport through barriers and topical drug delivery
TW200510425A (en) * 2003-08-13 2005-03-16 Japan Tobacco Inc Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor
KR20070086045A (ko) * 2004-11-12 2007-08-27 이데아 아게 피부 상태 치료에서의 확대된 표면 집합체
MX2007014038A (es) * 2005-05-12 2008-02-11 Glaxo Group Ltd Composicion de vacuna.
EP1885186B1 (en) * 2005-06-01 2015-09-02 California Institute Of Technology Method of targeted gene delivery using viral vectors
CA2651764A1 (en) * 2006-05-09 2007-11-22 Gerald V. Quinnan Hiv-1 immunogenic compositions
WO2008011636A2 (en) * 2006-07-21 2008-01-24 California Institute Of Technology Targeted gene delivery for dendritic cell vaccination
US9717788B2 (en) * 2007-03-02 2017-08-01 Glaxosmithkline Biologicals Sa Method of inducing an immune response against HIV employing HIV immunogens, adenoviral vectors encoding said immunogens, and adjuvant
AU2008223951B2 (en) * 2007-03-02 2014-03-27 Glaxosmithkline Biologicals S.A. Novel method and compositions
WO2008109785A2 (en) * 2007-03-06 2008-09-12 Rutgers, The State University Hiv reverse transcriptase compositions and methods
JP2010522761A (ja) * 2007-03-26 2010-07-08 インターナショナル エイズ バクシーン イニシアティブ 改変ｍｖａウイルスｈｉｖ−１ベクターを用いて免疫応答を誘発する方法
SI2148697T1 (sl) 2007-05-24 2013-01-31 Glaxosmithkline Biologicals S.A. Liofilizirani sestavek, ki vsebuje CpG in WT-1
AU2008339984A1 (en) * 2007-12-21 2009-07-02 Glaxosmithkline Biologicals S.A. Vaccine
NZ594540A (en) * 2008-07-16 2012-01-12 Baylor Res Inst Hiv vaccine based on targeting maximized gag and nef antigen to dendritic cells using antibodies
GB0815872D0 (en) * 2008-09-01 2008-10-08 Pasteur Institut Novel method and compositions
EP2344143A1 (en) 2008-09-09 2011-07-20 Mukesh Harilal Shukla Bioactive composition for the treatment of the hiv/aids, method for manufacturing and using the same
TR201819229T4 (tr) 2009-07-24 2019-01-21 Immune Design Corp Entegre olmayan lentiviral vektörler.
MX2012011189A (es) 2010-03-26 2013-02-07 Glaxosmithkline Biolog Sa Vacuna contra el virus e inmunodeficiencia humana.
SI2569008T1 (sl) 2010-05-14 2020-02-28 Baxalta Incorporated Himere OSPA in njihova uporaba v cepivih
EP2621528A1 (en) * 2010-09-27 2013-08-07 GlaxoSmithKline Biologicals S.A. Vaccine
JP2012120506A (ja) * 2010-12-10 2012-06-28 Tosoh Corp Ａｍｖ逆転写酵素遺伝子、該遺伝子によりコードされるａｍｖ逆転写酵素及び該遺伝子を用いるａｍｖ逆転写酵素の製造方法
GB201022007D0 (en) 2010-12-24 2011-02-02 Imp Innovations Ltd DNA-sensor
JP2013146235A (ja) * 2012-01-20 2013-08-01 Tosoh Corp トリ骨髄芽細胞腫ウイルス逆転写酵素の製造方法
EP2620446A1 (en) 2012-01-27 2013-07-31 Laboratorios Del Dr. Esteve, S.A. Immunogens for HIV vaccination
US9713635B2 (en) 2012-03-30 2017-07-25 Immune Design Corp. Materials and methods for producing improved lentiviral vector particles
US8323662B1 (en) 2012-03-30 2012-12-04 Immune Design Corp. Methods useful for generating highly mannosylated pseudotyped lentiviral vector particles comprising a Vpx protein
ES2707288T3 (es) 2012-03-30 2019-04-03 Immune Design Corp Partículas de vectores lentivíricos que tienen eficiencia de transducción mejorada para células que expresan DC-SIGN
US9782473B2 (en) 2013-03-26 2017-10-10 Globeimmune, Inc. Compositions and methods for the treatment or prevention of human immunodeficiency virus infection
MA40238A (fr) 2014-07-11 2017-05-17 Gilead Sciences Inc Modulateurs de récepteurs de type toll pour le traitement du vih
KR102014518B1 (ko) 2017-01-05 2019-08-26 서울대학교산학협력단 HIV 1의 p24 단백질을 발현하는 벡터가 도입된 재조합 마이코박테리움 스메그마티스 균주 및 이를 포함하는 백신
GB201812647D0 (en) 2018-08-03 2018-09-19 Chancellor Masters And Scholars Of The Univ Of Oxford Viral vectors and methods for the prevention or treatment of cancer
KR20220047277A (ko) 2019-07-16 2022-04-15 길리애드 사이언시즈, 인코포레이티드 Hiv 백신, 및 이의 제조 및 사용 방법
AU2020384323A1 (en) 2019-11-14 2022-06-02 Aelix Therapeutics, S.L. Dosage regimens for vaccines
EP4126028A1 (en) 2020-03-27 2023-02-08 Svenska Vaccinfabriken Produktion AB Compositions and methods for treating and preventing coronaviruses
AU2022207422A1 (en) 2021-01-14 2023-07-27 Gilead Sciences, Inc. Hiv vaccines and methods of using
TW202330575A (zh) 2021-09-29 2023-08-01 瑞典商斯文斯卡疫苗生產股份有限公司 用於治療及預防冠狀病毒之組成物及方法

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
US4372945A (en) 1979-11-13 1983-02-08 Likhite Vilas V Antigen compounds
IL61904A (en) 1981-01-13 1985-07-31 Yeda Res & Dev Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
DE3300234A1 (de) 1983-01-05 1984-07-05 Display-Design GmbH für moderne Verkaufsförderungsmittel und Raumaussstattung, 6233 Kelkheim Etagenturm zur warenausstellung
CA1331443C (en) 1987-05-29 1994-08-16 Charlotte A. Kensil Saponin adjuvant
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
DK643188A (da) * 1987-11-24 1989-05-25 Smithkline Biolog Ekspression af hiv-proteiner i e.coli og s.cerevisiae
US5221610A (en) 1988-05-26 1993-06-22 Institut Pasteur Diagnostic method and composition for early detection of HIV infection
EP0468520A3 (en) 1990-07-27 1992-07-01 Mitsui Toatsu Chemicals, Inc. Immunostimulatory remedies containing palindromic dna sequences
ZA929870B (en) 1991-12-23 1993-08-18 Duphar Int Res Adjuvants
KR0172970B1 (ko) 1992-06-17 1999-02-01 김영길 Aids백신에 유용한 키메릭 단백 및 그의 제조방법
EP0671948B1 (en) 1992-06-25 1997-08-13 SMITHKLINE BEECHAM BIOLOGICALS s.a. Vaccine composition containing adjuvants
ES2109685T5 (es) 1993-03-23 2005-09-01 Smithkline Beecham Biologicals S.A. Composiciones para vacunas que contienen monofosforil-lipido a 3-o-desacilado.
DE69434151D1 (de) 1993-05-18 2004-12-30 Biomolecular Res Inst Ltd Therapeutische inhaltsstoffe
AU700485B2 (en) 1993-11-17 1999-01-07 Om Pharma Glucosamine disaccharides, method for their preparation, pharmaceutical composition comprising same, and their use
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
CA2560114A1 (en) 1994-07-15 1996-02-01 The University Of Iowa Research Foundation Immunomodulatory oligonucleotides
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
GB9620795D0 (en) 1996-10-05 1996-11-20 Smithkline Beecham Plc Vaccines
AU4255397A (en) 1996-09-06 1998-03-26 Trustees Of The University Of Pennsylvania, The Chimpanzee adenovirus vectors
US6610661B1 (en) 1996-10-11 2003-08-26 The Regents Of The University Of California Immunostimulatory polynucleotide/immunomodulatory molecule conjugates
GB9711990D0 (en) 1997-06-11 1997-08-06 Smithkline Beecham Biolog Vaccine
AU734180B2 (en) 1997-08-29 2001-06-07 Antigenics Llc Compositions comprising the adjuvant qs-21 and polysorbate or cyclodextrin as excipient
DE69838992T2 (de) 1997-09-05 2008-12-24 Glaxosmithkline Biologicals S.A., Rixensart Öl-in-Wasser Emulsionen mit Saponinen
GB9718901D0 (en) 1997-09-05 1997-11-12 Smithkline Beecham Biolog Vaccine
GB9720585D0 (en) 1997-09-26 1997-11-26 Smithkline Beecham Biolog Vaccine
ATE435034T1 (de) 1998-08-04 2009-07-15 Jackson H M Found Military Med Expression und charakterisierung eines hiv-1 hüllproteins, das mit einer breitreaktiven neutralisierenden antikörperantwort assoziiert ist.
JP2003516741A (ja) 1999-12-17 2003-05-20 メルク エンド カムパニー インコーポレーテッド コドン最適化ＨＩＶ−１Ｎｅｆ及び修飾ＨＩＶ−１Ｎｅｆを発現するポリヌクレオチドワクチン
CA2392877C (en) * 1999-12-23 2011-11-15 Tomas Hanke Improvements in or relating to immune responses to hiv
US20020155127A1 (en) * 2000-06-02 2002-10-24 Danher Wang Genetic vaccine against human immunodeficiency virus
WO2002022080A2 (en) 2000-09-15 2002-03-21 Merck & Co., Inc. Enhanced first generation adenovirus vaccines expressing codon optimized hiv1-gag, pol, nef and modifications
CU23235A1 (es) * 2001-02-28 2007-09-26 Ct Ingenieria Genetica Biotech POXVIRUS RECOMBINANTES PARA PROTEINAS QUIMéRICAS DEL VIRUS DE LA INMUNODEFICIENCIA HUMANA Y SU APLICACION EN LA TERAPéUTICA Y LA PREVENCION DEL SIDA
JP2005500336A (ja) * 2001-07-25 2005-01-06 ニューヨーク・ユニバーシティ 感染および癌に対するワクチンのためのアジュバントとしてのグリコシルセラミドの使用
JP4601956B2 (ja) 2001-09-20 2010-12-22 グラクソ グループ リミテッド Ｈｉｖ−ｇａｇのコドン最適化ｄｎａワクチン
SG2013034475A (en) 2001-11-21 2016-10-28 Univ Pennsylvania Simian adenovirus nucleic acid and amino acid sequences, vectors containing same, and methods of use
AU2002360429A1 (en) 2001-11-26 2003-06-10 Avigen, Inc. Methods for producing stocks of recombinant aav virions
US20030190308A1 (en) * 2002-03-19 2003-10-09 Braun Ralph P. Adjuvant
AU2003216852B2 (en) * 2002-03-19 2008-09-11 Glaxo Group Limited Imidazoquinolineamines as adjuvants in HIV DNA vaccination
KR20050010040A (ko) * 2002-06-11 2005-01-26 글락소스미스클라인 바이오로지칼즈 에스.에이. 면역원성 조성물
GB0225786D0 (en) 2002-11-05 2002-12-11 Glaxo Group Ltd Vaccine
GB0225788D0 (en) 2002-11-05 2002-12-11 Glaxo Group Ltd Vaccine
US7501503B2 (en) * 2002-12-31 2009-03-10 Mcgill University Compositions and methods for inhibiting RNase H activity of retroid reverse transcriptase
WO2005030964A1 (en) 2003-09-24 2005-04-07 Oxxon Therapeutics Limited Hiv pharmaccines
US20050175627A1 (en) 2003-09-24 2005-08-11 Oxxon Therapeutics Ltd. HIV pharmaccines

Also Published As

Publication number Publication date
IL180947A0 (en) 2007-07-04
RU2007104088A (ru) 2008-09-10
JP6007212B2 (ja) 2016-10-12
JP2008507987A (ja) 2008-03-21
CY1109667T1 (el) 2014-08-13
JP2014239687A (ja) 2014-12-25
EP2280073B1 (en) 2014-06-11
PE20060577A1 (es) 2006-08-07
CN102633866A (zh) 2012-08-15
MY145614A (en) 2012-03-15
NO20070988L (no) 2007-05-04
EP1773999A2 (en) 2007-04-18
DK1773999T3 (da) 2010-01-18
WO2006013106A3 (en) 2006-08-17
SG155206A1 (en) 2009-09-30
EP1773999B1 (en) 2009-09-23
MX2007001515A (es) 2007-09-07
CN102633866B (zh) 2015-04-15
BRPI0514108A (pt) 2008-05-27
TW200621806A (en) 2006-07-01
TWI365191B (en) 2012-06-01
ES2486669T3 (es) 2014-08-19
PL1773999T3 (pl) 2010-02-26
ZA200700771B (en) 2009-04-29
EP2130921B1 (en) 2013-11-20
EP2280073A3 (en) 2011-06-29
ES2334044T3 (es) 2010-03-04
KR20070041765A (ko) 2007-04-19
AU2005268856A1 (en) 2006-02-09
EP2280073A2 (en) 2011-02-02
SI1773999T1 (sl) 2010-01-29
IL207575A0 (en) 2011-07-31
GB0417494D0 (en) 2004-09-08
ES2445453T3 (es) 2014-03-03
WO2006013106A2 (en) 2006-02-09
MA28983B1 (fr) 2007-11-01
ATE443769T1 (de) 2009-10-15
HK1108168A1 (en) 2008-05-02
EP2130921A2 (en) 2009-12-09
CA2575898A1 (en) 2006-02-09
HRP20090678T1 (hr) 2010-01-31
AR050102A1 (es) 2006-09-27
CN101035897B (zh) 2012-02-01
PT1773999E (pt) 2009-12-16
RU2441878C2 (ru) 2012-02-10
JP5629647B2 (ja) 2014-11-26
DE602005016810D1 (de) 2009-11-05
CN101035897A (zh) 2007-09-12
JP2011234722A (ja) 2011-11-24
US20100184836A1 (en) 2010-07-22
US7612173B2 (en) 2009-11-03
CA2575898C (en) 2015-09-29
KR101501495B1 (ko) 2015-03-11
US20070243203A1 (en) 2007-10-18
EP2130921A3 (en) 2010-03-03
AU2005268856B2 (en) 2012-05-24
NZ552976A (en) 2010-01-29

Similar Documents

Publication Publication Date Title
AR080216A2 (es) Composiciones farmaceuticas que contienen una proteina de fusion de vih
CY1120377T1 (el) Στερεη φαρμακευτικη δοσολογικη φαρμακοτεχνικη μορφη που περιεχει λοπιναβιρη
ECSP045491A (es) Nueva sal formiato de o-desmetil venlafaxina
CR11575A (es) Vacuna
UY28348A1 (es) Compuestos novedosos
AR042051A1 (es) Tratamiento combinado contra el cancer con un compuesto anti-cancerigeno activado por glutationa s- transferasa (gst) y otro tratamiento contra el cancer
CR8402A (es) Indazol-o-glucosidos sustitutos
CO5560591A2 (es) Vacunas de adn optimizadas por el codon vih-gag
AR033023A1 (es) Composicion topica
ECSP055529A (es) Composicion herbicida
CL2009001899A1 (es) Composicion farmaceutica que comprende: i) un antagonista del receptor de at1 o una sal, ii) un sensibilizante a la insulina o una sal y iii) un vehiculo farmaceuticamente aceptable; uso para la prevencion, demora de progreso o tratamiento de hipertension, diabetes, entre otras (div. sol. 2034-01).
PE20040875A1 (es) Composiciones para el cuidado bucal
AR056137A1 (es) Un conjugado peptido inmunoglobulina y su uso como antiviral
CR8251A (es) Composiciones de hiv inmunogenicas y metodos relacionados
ECSP21072036A (es) Composición farmacéutica que contiene acetaminofeno e ibuprofeno
DE60111503D1 (de) Pharmazeutische zusammensetzungen enthaltend terbinafin
AR043016A2 (es) Un compuesto antimigranico eletriptan y composicion farmaceutica que lo contiene
AR040764A1 (es) Formulaciones farmaceuticas de epinastina, pseudoefedrina y metilefedrina
ATE335507T1 (de) Impfstoff gegen infektionen mit onkoviren, wie dem felinen leukosevirus der katze
ATE357220T1 (de) Pharmazeutische zusammensetzung mit modifizierter freisetzung
AR047880A1 (es) COMBINACIoN DE UN INHIBIDOR DE RENINA Y DIURÉTICOS
CO5660272A2 (es) Vacunas bovinas con adyuvantes
CY1106200T1 (el) Αντισωματα εναντια σε κασπαση-8, παρασκευη και χρηση τους
CR6835A (es) Un paquete combinado usado en el tratamiento de la malaria
SV2006002224A (es) Composicion farmaceutica ref. bhco41368-sv

Legal Events

Date Code Title Description
FC Refusal